Literature DB >> 15679782

Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy.

Christoph Wiesner1, Jesco Pfitzenmaier, Andreas Faldum, Rolf Gillitzer, Sebastian W Melchior, Joachim W Thüroff.   

Abstract

UNLABELLED: The first paper in this section, from Mainz, attempts to identify the clinical variables associated with the prevalence of lymph node metastases in non-muscle invasive bladder cancer. The authors found that delay in cystectomy in this potentially dangerous type of tumour is to be avoided, with a higher incidence of lymph node metastases as the number of transurethral resections increases. A paper from Austria shows that in renal carcinoma the pT1 subdivision is associated with differences in conventional histopathology and expression of biomarkers.
OBJECTIVE: To identify clinical variables associated with the prevalence of lymph node metastases (LNMs) in patients with non-muscle invasive transitional cell carcinoma (TCC) of the bladder treated with radical cystectomy. PATIENTS AND METHODS: Of 866 patients treated by radical cystectomy and pelvic lymphadenectomy between 1989 and 2002, 219 had non-muscle invasive TCC of the bladder. A retrospective evaluation of these patients included univariate and multivariate analyses of sex, age, number of transurethral resections of the bladder tumour (TURBTs), interval between first TURBT and cystectomy, adjuvant therapy, maximum histopathological tumour stage and grade at TURBT, and tumour upstaging in the cystectomy specimen.
RESULTS: LNMs were diagnosed in 33 patients (15%). After multivariate analysis modelling, the number of TURBTs and tumour upstaging in the cystectomy specimen were correlated with the prevalence of LNMs at cystectomy. The number of TURBTs increased the prevalence of LNMs from 8% in patients with one TURBT to 24% in those with two to four TURBTs. Tumour upstaging in the cystectomy specimen increased the prevalence of LNMs from 4% to 36%.
CONCLUSION: Inappropriate delay and inadequate staging of high-grade non-muscle invasive TCC of the bladder are to be avoided. The present multivariate analysis showed that the number of TURBTs and tumour upstaging in the cystectomy specimen correlated with an increased prevalence of LNMs.

Entities:  

Mesh:

Year:  2005        PMID: 15679782     DOI: 10.1111/j.1464-410X.2005.05287.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  15 in total

1.  Selecting patients for immediate cystectomy.

Authors:  Shahrokh F Shariat
Journal:  Rev Urol       Date:  2007

2.  The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy.

Authors:  John P Stein; David F Penson
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

Review 3.  Improving outcomes with radical cystectomy for high-grade invasive bladder cancer.

Authors:  John P Stein
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

4.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

5.  Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance.

Authors:  José I López; Javier C Angulo
Journal:  Int Urol Nephrol       Date:  2009-03-12       Impact factor: 2.370

6.  [Prevalence of lymph node metastases in non-muscle-invasive bladder cancer. Delay of radical cystectomy and upstaging in the cystectomy specimen as risk factors].

Authors:  C Wiesner; C Thomas; A Salzer; R Gillitzer; C Hampel; J W Thüroff
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

7.  Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3).

Authors:  Richard E Hautmann; Bjoern G Volkmer; Kilian Gust
Journal:  World J Urol       Date:  2009-03-25       Impact factor: 4.226

Review 8.  How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

Authors:  Seok Joong Yun; Seon-Kyu Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-06-10

Review 9.  Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?

Authors:  Boris Gershman; Stephen A Boorjian; Richard E Hautmann
Journal:  Bladder Cancer       Date:  2015-09-05

10.  Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Authors:  Peng Ge; Li Wang; Meng Lu; Lijun Mao; Wang Li; Rumin Wen; Jian Lin; Junqi Wang; Jiacun Chen
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.